Aileron Therapeutics, Inc Garners $40,000,000 Series D Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8236efec-9d9d-45f4-9e7c-93dfda02f1dc&Preview=1 -
Date
6/8/2009 -
Company Name
Aileron Therapeutics, Inc -
Mailing Address
840 Memorial Drive, 2nd Floor Cambridge, MA 02139 -
Company Description
Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics
for the treatment of cancer and other diseases. Aileron’s technology is the first and
only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs. -
Website
http://www.aileronrx.com -
Transaction Type
Venture Equity -
Transaction Amount
$40,000,000 -
Transaction Round
Series D -
Proceeds Purposes
Proceeds from the financing will be used to advance Aileron’s lead Stapled Peptide program toward clinical trials in 2010 and to further advance the Stapled Peptide platform and programs in oncology, immune/inflammation, metabolic disease, and infectious disease. -
M&A Terms
-
Venture Investor
SR One -
Venture Investor
GlaxoSmithKline -
Venture Investor
Excel Medical Fund -
Venture Investor
Apple Tree Partners -
Venture Investor
Novartis Venture Fund -
Venture Investor
Lilly Ventures -
Venture Investor
Roche Venture Fund
